Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway

Gao,Xinghua; Liu,Jikai; Fan,Daming; Li,Xiaofeng; Fang,Zhiqing; Yan,Keqiang; Fan,Yidong

doi:10.3892/or.2021.8244

Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway

Authors:
- Xinghua Gao
- Jikai Liu
- Daming Fan
- Xiaofeng Li
- Zhiqing Fang
- Keqiang Yan
- Yidong Fan
View Affiliations

Affiliations: Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Pathology, Jinan Central Hospital, Jinan, Shandong 250013, P.R. China
Published online on: December 20, 2021 https://doi.org/10.3892/or.2021.8244
Article Number: 33

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although gemcitabine (GEM) has been used to treat bladder cancer (BC) for a number of years, severe adverse events or drug resistance frequently develops. A series of drugs have been proved to sensitize patients to GEM and reduce the side effects. The aim of the present study was to evaluate the potential effects of berberine (BER) on GEM‑induced cytotoxicity in BC and to explore the possible underlying mechanisms. T24 and 5637 human BC cell lines were treated with GEM and/or BER before cell proliferation, apoptosis and migration were studied. Oncomine databases and Gene Expression Profiling Interactive Analysis (GEPIA) were used to retrieve RAD51 recombinase (Rad51) mRNA expression. Overexpression plasmid or specific Rad51 small interfering RNA were used to examine the role of Rad51 in drug‑treated BC cells. BC model mice were administered with GEM and/or BER before changes in tumor volume, size and Ki67 expression were assessed. BER enhanced GEM‑induced cytotoxicity, apoptosis and inhibition of migration, whilst attenuating the GEM‑induced upregulation of phosphorylated Akt and Rad51 expression. According to Oncomine and GEPIA analyses, Rad51 was found to be significantly upregulated in BC tissues compared with that in normal tissues, where there was a weak positive correlation between Rad51 and Akt1 expression. Knockdown of Rad51 enhanced GEM‑induced cytotoxicity, whilst overexpression of Rad51 reversed the suppressed cell viability induced by BER and GEM. Inactivation of the PI3K/Akt pathway by LY294002 or BER enhanced GEM‑induced cytotoxicity and downregulated Rad51 expression, whilst overexpression of constitutively active Akt restored Rad51 expression and cell viability that was previously decreased by BER and GEM. BER additively inhibited tumor growth and Ki67 expression when combined with GEM in vivo. These results suggest that BER can enhance GEM‑induced cytotoxicity in BC by downregulating Rad51 expression through inactivating the PI3K/Akt pathway, which may represent a novel therapeutic target for BC treatment.

View Figures

View References

1	Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 71:96–108. 2017. View Article : Google Scholar : PubMed/NCBI
2	Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, et al: European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 76:639–657. 2019. View Article : Google Scholar : PubMed/NCBI
3	Gakis G: Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. Eur Urol Focus. 6:632–638. 2020. View Article : Google Scholar : PubMed/NCBI
4	von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000. View Article : Google Scholar : PubMed/NCBI
5	Yu C, Hequn C, Jinbo C, Feng Z, Xiongbing Z and Jian D: Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis. J Cancer Res Ther. 14:1260–1265. 2018.PubMed/NCBI
6	Isono M, Hoffmann MJ, Pinkerneil M, Sato A, Michaelis M, Cinatl J Jr, Niegisch G and Schulz WA: Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. J Exp Clin Cancer Res. 36:12017. View Article : Google Scholar : PubMed/NCBI
7	Xie D, Zhang H and Shang C: Long non-coding RNA CDKN2B antisense RNA 1 gene inhibits Gemcitabine sensitivity in bladder urothelial carcinoma. J Cancer. 9:2160–2166. 2018. View Article : Google Scholar : PubMed/NCBI
8	Foschini F, Formisano L, Marciano R, Mozzillo E, Carratù A, Napolitano F, Santaniello A, De Placido P, Cascetta P, Servetto A, et al: FOLFIRINOX after first-line gemcitabine-based chemotherapy in metastatic pancreatic cancer: A mono-institutional experience. Ann Oncol. 30 (Suppl 4):iv52–iv53. 2019. View Article : Google Scholar
9	Zhang X, Wang D, Li Z, Jiao D, Jin L, Cong J, Zheng X and Xu L: Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer. Front Immunol. 11:3312020. View Article : Google Scholar : PubMed/NCBI
10	Kassouf W, Highshaw R, Nelkin GM, Dinney CP and Kamat AM: Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol. 176:1642–1647. 2006. View Article : Google Scholar : PubMed/NCBI
11	Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Gaivão I, Cardoso ML, Colaço A, Santos L and Oliveira P: Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines. J Toxicol Environ Health A. 75:788–799. 2012. View Article : Google Scholar : PubMed/NCBI
12	Yoon CY, Lee JS, Kim BS, Jeong SJ, Hong SK, Byun SS and Lee SE: Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J Urol. 52:55–63. 2011. View Article : Google Scholar : PubMed/NCBI
13	Guo Z, Hu X, Xing Z, Xing R, Lv R, Cheng X, Su J, Zhou Z, Xu Z, Nilsson S, et al: Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. Mol Cell Biochem. 406:111–119. 2015. View Article : Google Scholar : PubMed/NCBI
14	Liu Z, Liu C, Yan K, Liu J, Fang Z and Fan Y: Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway. Front Oncol. 11:6155682021. View Article : Google Scholar : PubMed/NCBI
15	Tang QL, Lai ML, Zhong YF, Wang AM, Su JK and Zhang MQ: Antinociceptive effect of berberine on visceral hypersensitivity in rats. World J Gastroenterol. 19:4582–4589. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lin X and Zhang N: Berberine: Pathways to protect neurons. Phytother Res. 32:1501–1510. 2018. View Article : Google Scholar : PubMed/NCBI
17	Imenshahidi M and Hosseinzadeh H: Berberine and barberry (Berberis vulgaris): A clinical review. Phytother Res. 33:504–523. 2019. View Article : Google Scholar : PubMed/NCBI
18	Mohammadinejad R, Ahmadi Z, Tavakol S and Ashrafizadeh M: Berberine as a potential autophagy modulator. J Cell Physiol. 234:14914–14926. 2019. View Article : Google Scholar : PubMed/NCBI
19	Jiang SX, Qi B, Yao WJ, Gu CW, Wei XF, Zhao Y, Liu YZ and Zhao BS: Berberine displays antitumor activity in esophageal cancer cells in vitro. World J Gastroenterol. 23:2511–2518. 2017. View Article : Google Scholar : PubMed/NCBI
20	Tian Y, Zhao L, Wang Y, Zhang H, Xu D, Zhao X, Li Y and Li J: Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells. Asian J Androl. 18:607–612. 2016. View Article : Google Scholar : PubMed/NCBI
21	Hou D, Xu G, Zhang C, Li B, Qin J, Hao X, Liu Q, Zhang X, Liu J, Wei J, et al: Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death Dis. 8:e30702017. View Article : Google Scholar : PubMed/NCBI
22	Yan K, Zhang C, Feng J, Hou L, Yan L, Zhou Z, Liu Z, Liu C, Fan Y, Zheng B, et al: Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells. Eur J Pharmacol. 661:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zhuo Y, Chen Q, Chen B, Zhan X, Qin X, Huang J and Lv X: Berberine promotes antiproliferative effects of epirubicin in T24 bladder cancer cells by enhancing apoptosis and cell cycle arrest. Int J Clin Pharmacol Ther. 55:32–40. 2017. View Article : Google Scholar : PubMed/NCBI
24	Godin SK, Sullivan MR and Bernstein KA: Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication. Biochem Cell Biol. 94:407–418. 2016. View Article : Google Scholar : PubMed/NCBI
25	Haber JE: DNA Repair: The Search for Homology. BioEssays. 40:e17002292018. View Article : Google Scholar : PubMed/NCBI
26	Nagathihalli NS and Nagaraju G: RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta. 1816:209–218. 2011.PubMed/NCBI
27	Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, et al: In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Mol Ther Nucleic Acids. 4:e2702015. View Article : Google Scholar : PubMed/NCBI
28	Hong KJ, Hsu MC and Hung WC: RECK impedes DNA repair by inhibiting the erbB/JAB1/Rad51 signaling axis and enhances chemosensitivity of breast cancer cells. Am J Cancer Res. 5:2422–2430. 2015.PubMed/NCBI
29	Wang B, Hou D, Liu Q, Wu T, Guo H, Zhang X, Zou Y, Liu Z, Liu J, Wei J, et al: Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol Ther. 16:1548–1556. 2015. View Article : Google Scholar : PubMed/NCBI
30	Lee JO, Kang MJ, Byun WS, Kim SA, Seo IH, Han JA, Moon JW, Kim JH, Kim SJ, Lee EJ, et al: Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51. Breast Cancer Res. 21:1152019. View Article : Google Scholar : PubMed/NCBI
31	Tsai MS, Kuo YH, Chiu YF, Su YC and Lin YW: Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J Pharmacol Exp Ther. 335:830–840. 2010. View Article : Google Scholar : PubMed/NCBI
32	Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C, Feng S, Guo H, Xu B, Yang Q, et al: Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One. 6:e234272011. View Article : Google Scholar : PubMed/NCBI
33	Sanchez-Carbayo M, Socci ND, Lozano J, Saint F and Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 24:778–789. 2006. View Article : Google Scholar : PubMed/NCBI
34	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45((W1)): W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
35	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
36	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, . Guide for the Care and Use of Laboratory Animals. 8th edition. The National Academies Press (US); Washington, DC: 2011
37	Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
38	Ko JC, Chen JC, Wang TJ, Zheng HY, Chen WC, Chang PY and Lin YW: Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol. 105:91–100. 2016. View Article : Google Scholar : PubMed/NCBI
39	Jabbarzadeh Kaboli P, Rahmat A, Ismail P and Ling KH: Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur J Pharmacol. 740:584–595. 2014. View Article : Google Scholar : PubMed/NCBI
40	Yin H, Yang X, Gu W, Liu Y, Li X, Huang X, Zhu X, Tao Y, Gou X and He W: HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation. Oncotarget. 8:71642–71656. 2017. View Article : Google Scholar : PubMed/NCBI
41	Takeuchi H, Mmeje CO, Jinesh GG, Taoka R and Kamat AM: Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells. Oncol Rep. 34:2738–2744. 2015. View Article : Google Scholar : PubMed/NCBI
42	Miller WH Jr, Schipper HM, Lee JS, Singer J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res. 62:3893–3903. 2002.PubMed/NCBI
43	Takeuchi H, Taoka R, Mmeje CO, Jinesh GG, Safe S and Kamat AM: CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. Urol Oncol. 34:337.e11–8. 2016. View Article : Google Scholar : PubMed/NCBI
44	Wang X, Bai Y, Zhang F, Yang Y, Feng D, Li A, Yang Z, Li D, Tang Y, Wei X, et al: Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder. OncoTargets Ther. 13:9543–9558. 2020. View Article : Google Scholar : PubMed/NCBI
45	Liu Z, Liu Q, Xu B, Wu J, Guo C, Zhu F, Yang Q, Gao G, Gong Y and Shao C: Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. Mutat Res. 662:75–83. 2009. View Article : Google Scholar : PubMed/NCBI
46	Huang J, Feng W, Li S, Tang H, Qin S, Li W, Gong Y, Fang Y, Liu Y, Wang S, et al: Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/Protein Kinase B (PI3K/AKT) Signaling Pathways. Curr Pharm Des. 27:565–574. 2021. View Article : Google Scholar : PubMed/NCBI